目标:关于幽门螺杆菌(H.儿童缺乏幽门螺杆菌)相关粘膜相关淋巴组织(MALT)淋巴瘤。我们的目的是描述诊断,管理,和儿童幽门螺杆菌相关MALT淋巴瘤的结果。
方法:2010-2022年期间诊断为幽门螺杆菌相关性MALT淋巴瘤的儿科患者的回顾性多中心病例系列。
结果:五个孩子,其中三个女性,已确定。诊断时的平均年龄为14.6±2.4岁。临床表现包括腹痛(5/5),恶心(3/5),减肥,盗汗,反复发烧(1/5),和缺铁性贫血(2/5)。胃窦和身体的内窥镜检查结果包括脆弱和充血的粘膜,大溃疡,广泛的结节,和渗出物。所有胃粘膜活检均符合MALT淋巴瘤,幽门螺杆菌阳性(通过Giemsa染色)。所有患者都接受了三联疗法(阿莫西林,硝基咪唑,或者大环内酯,和质子泵抑制剂,14天),根除幽门螺杆菌。在最后一次随访中,所有人的组织学发现都得到了完全解决。在一个病人中,幽门螺杆菌根除后12个月,MALT淋巴瘤的组织学仍然存在,只有18个月的活检没有残留病。
结论:在这一系列小儿MALT淋巴瘤中,在所有患者中发生疾病的完全解决,然而,组织学缓解延迟了一个。这支持了内窥镜随访的重要性。
OBJECTIVE: Data regarding Helicobacter pylori (H. pylori)-associated mucosa-associated lymphoid tissue (MALT) lymphoma in children are lacking. We aimed to characterize the diagnosis, management, and outcome of H. pylori-associated MALT lymphoma in pediatric patients.
METHODS: A retrospective multicenter
case series of the pediatric patients with H. pylori-associated MALT lymphoma who were diagnosed during 2010-2022.
RESULTS: Five children, of them three females, were identified. The mean age at diagnosis was 14.6 ± 2.4 years. The clinical presentation included abdominal pain (5/5), nausea (3/5), weight loss, night sweats, recurrent fever (1/5), and iron deficiency anemia (2/5). Endoscopic findings in both the stomach antrum and body included a fragile and hyperemic mucosa, large ulcers, extensive nodularity, and exudate. All the biopsies from the gastric mucosa were consistent with MALT lymphoma, and positive for H. pylori (by Giemsa stain). All the patients received triple therapy (amoxicillin, nitroimidazole, or a macrolide, and a proton pump inhibitor, for 14 days), and achieved H. pylori eradication. All had complete resolution of histological findings at the last follow-up. In one patient, the histology of MALT lymphoma persisted 12 months after H. pylori eradication, and only the 18-month-biopsy was free of residual disease.
CONCLUSIONS: In this series of pediatric MALT lymphoma, complete resolution of disease occurred in all the patients, yet histological remission was delayed in one. This supports the importance of endoscopic follow-up.